


Stabilis



Dopamine hydrochloride



Nekomercijalni

Abbodop	Danska, Finska, Švedska
Cardiopal	Kolumbija
Dopadic	Iran
Dopadren	Turska
Dopamin	Austrija, Njemačka, Saudijska Arabija, Švicarska
Dopamina	Argentina, Čile, Ekvador, Italija, Kolumbija, Meksiko, Peru, Španjolska, Venecuela
Dopamine	Francuska, Kanada, Luksemburg, Maroko, Nizozemska, S A D
Dopaminum	Poljska
Dopmin	Danska, Finska, Malezija, Turska
Dynatra	Belgija, Luksemburg, Nizozemska
Giludop	Danska, Grčka, Švedska
Intropin	Egipat
Miocina	Meksiko
Myofast	Kolumbija
Myotil	Texte introuvable (616,)
Paldopa	Peru
Revivan	Meksiko
Zetarina	Meksiko



Stabilizacija rješenja

		0,8 mg/ml	23-25°C		48			732
		0,8 mg/ml	23-25°C		48			732
		0,8 mg/ml	5°C		7			732
		1 mg/ml	25°C		36			1249
	RL	0,8 mg/ml	23-25°C		48			732
		0,8 mg/ml	25°C		24			732
		3,2 mg/ml	5°C		14			197
		6,4 mg/ml	23°C		24			192

		10 mg/ml	23°C		84			3712
		2 mg/ml	23°C		84			3712
		30 mg/ml	23°C		84			3712
		0,5 mg/ml	25°C		7			1820
		0,5 mg/ml	4°C		120			1820
		10 mg/ml	23°C		84			3712
		2 mg/ml	23°C		84			3712
		30 mg/ml	23°C		84			3712
		4 mg/ml	23-25°C		48			206
		4 mg/ml	25°C		24			196
		4 mg/ml	4°C		48			206
		10 mg/ml	23°C		84			3712
		2 mg/ml	23°C		84			3712
		30 mg/ml	23°C		84			3712
		0,4 >> 1 mg/ml	25°C		24			1698
		0,4 >> 3,2 mg/ml	25°C		48			3638
		0,4 >> 1 mg/ml	2-8°C		14			1698
		0,4 >> 1 mg/ml	25°C		24			1698
		0,4 >> 3,2 mg/ml	25°C		48			3638



Stabilnost mješavine

		0,8 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
		0,8 mg/ml	25°C		Bretylium tosilate : 10 mg/ml	48		705
		0,8 mg/ml	40°C		Bretylium tosilate : 10 mg/ml	48		705
		0,8 mg/ml	4°C		Bretylium tosilate : 10 mg/ml	7		705
		1,6 mg/ml	20°C-25°C		Labetalol hydrochloride : 1 mg/ml	4		199
		5 mg/ml	22°C		Norepinephrine bitartrate : 0,06 mg/ml	24		3381
		3,1 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4		813
		0,8 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
		0,8 mg/ml	23°C-25°C		Heparin sodium : 20 UI/ml	24		738
		0,8 mg/ml	23°C-25°C		Lidocaine hydrochloride : 3,26 mg/ml	24		738

		0,8 mg/ml	23°C-25°C		Cefalotin sodium : 4 mg/ml	24		738
		0,8 mg/ml	23°C-25°C		Oxacillin sodium : 2 mg/ml	24		738
		0,8 mg/ml	23°C-25°C		Gentamicin sulfate : 0,32 mg/ml	24		738
		0,8 mg/ml	25°C		Bretylium tosilate : 10 mg/ml	48		705
		0,8 mg/ml	40°C		Bretylium tosilate : 10 mg/ml	48		705
		0,8 mg/ml	4°C		Bretylium tosilate : 10 mg/ml	7		705
	RL	0,8 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
		0,6 >> 40 mg/ml	25°C		Treprostnil : 0,004 >>0,076 mg/ml	4		4407
		0,6 mg/ml	25°C		Treprostnil : 0,5 mg/ml	4		4407
		0,8 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
PVC		0.1 & 1.6 mg/ml	25°C		Tirofiban : 25 µg/ml	4		1420
PVC		0,4 & 3,2 mg/ml	?		Ranitidine hydrochloride : 0,05 & 2 mg/ml	48		210
PVC		3,2 mg/ml	23°C		Flumazenil : 0,02 mg/ml	12		187
PVC		0.1 & 1.6 mg/ml	25°C		Tirofiban : 25 µg/ml	4		1420
PVC		0,4 & 3,2 mg/ml	?		Ranitidine hydrochloride : 0,05 & 2 mg/ml	48		210
PE		5 mg/ml	22°C		Norepinephrine bitartrate : 0,06 mg/ml	24		3381
PP		8 mg/ml	22-25°C		Dobutamine hydrochloride : 8 mg/ml	24		1506
PP		8 mg/ml	22-25°C		Methadone hydrochloride : 0.2 mg/ml	24		1506
PP		8 mg/ml	22-25°C		Dobutamine hydrochloride : 8 mg/ml	24		1506
PP		8 mg/ml	22-25°C		Methadone hydrochloride : 0.2 mg/ml	24		1506
		3,6 mg/ml	22°C-28°C		Daptomycin : 18,2 mg/ml	2		1937



Stabilizacijski faktor

				1965
				197
				1415
				732 3638
	pH >7			3638
	pH > 6			197
	pH = 5			1397



Kompatibilnosti

			
			336
			3595
			36
			4491
			3201
			4651
			240
			92
			3
			3759
			1036
			3823
			1036
			3824
			3638
			921
			3638
			4818
			1982
			1964
			402
			99
			1944
			1944

		Dopamine hydrochloride : 3.2 mg/ml Bivalirudin : 5 mg/ml		1713
		Dopamine hydrochloride : 0,8 mg/ml Bretylum tosilate : 10 mg/ml		705
		Dopamine hydrochloride : 0,8 mg/ml Bretylum tosilate : 10 mg/ml		705
		Dopamine hydrochloride : 7.2 mg/ml Caffeine : 10 mg/ml		4837
		Dopamine hydrochloride : 3.2 mg/ml Caffeine : 10 mg/ml		3964
		Dopamine hydrochloride : 7.2 mg/ml Caffeine : 10 mg/ml		4837
		Dopamine hydrochloride : 7,2 mg/ml Caffeine citrate : 20 mg/ml		4837
		Dopamine hydrochloride : 7,2 mg/ml Caffeine citrate : 20 mg/ml		4837
		Dopamine hydrochloride : 0.8 mg/ml Calcium chloride		738
		Dopamine hydrochloride : 3,2 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Dopamine hydrochloride : 6.4 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Dopamine hydrochloride Cefalotin sodium		3638
		Dopamine hydrochloride : 0.8 mg/ml Cefalotin sodium : 4 mg/ml		738
		Dopamine hydrochloride : 0.4 mg/ml Cefepime dihydrochloride : 125 mg/ml		2141
		Dopamine hydrochloride : 4.2 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Dopamine hydrochloride : 0.8 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Dopamine hydrochloride : 0.8 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Dopamine hydrochloride : 0.8 mg/ml Cefpirome sulfate : 50 mg/ml	RL	280
		Dopamine hydrochloride : 0.8 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Dopamine hydrochloride : 3,2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Dopamine hydrochloride : 3,2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Dopamine hydrochloride : 3,2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Dopamine hydrochloride : 0.4 mg/ml Ceftazidime : 125 mg/ml		2141
		Dopamine hydrochloride Ceftobiprole medocaril sodium		4650
		Dopamine hydrochloride : 3.2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Dopamine hydrochloride : 3.2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269

		Dopamine hydrochloride : 3.2 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Dopamine hydrochloride : 0.8 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Dopamine hydrochloride : 0.8 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Dopamine hydrochloride : 1.6 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Dopamine hydrochloride : 1.6 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Dopamine hydrochloride : 3.2 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Dopamine hydrochloride : 3.2 mg/ml Cladribine : 0.5 mg/ml		1496
		Dopamine hydrochloride : 3.2 mg/ml Cladribine : 0.015 mg/ml		1496
		Dopamine hydrochloride : 8 mg/ml Clonidine hydrochloride : 0.0075 mg/ml		1506
		Dopamine hydrochloride : 8 mg/ml Clonidine hydrochloride : 0.0075 mg/ml		1506
		Dopamine hydrochloride : 2 mg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
		Dopamine hydrochloride : 3.2 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Dopamine hydrochloride Conivaptan		3715
		Dopamine hydrochloride : 3,6 mg/ml Daptomycin : 18,2 mg/ml		1937
		Dopamine hydrochloride Daptomycin		2271
		Dopamine hydrochloride Dexketoprofen		4981
		Dopamine hydrochloride Dexmedetomidine		5042
		Dopamine hydrochloride : 3.2 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Dopamine hydrochloride : 0.8 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Dopamine hydrochloride : 1,6 mg/ml Diltiazem hydrochloride : 1 mg/ml		524
		Dopamine hydrochloride : 3.2 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
		Dopamine hydrochloride : 8 mg/ml Dobutamine hydrochloride : 8 mg/ml		1506
		Dopamine hydrochloride : 8 mg/ml Dobutamine hydrochloride : 8 mg/ml		1506
		Dopamine hydrochloride : 1.6 mg/ml Dobutamine hydrochloride : 1 mg/ml		1058
		Dopamine hydrochloride : 5,52 mg/ml Dobutamine hydrochloride : 0,17 mg/ml		1221
		Dopamine hydrochloride : 1.6 mg/ml Dobutamine hydrochloride : 1 mg/ml		1058

		Dopamine hydrochloride : 3.2 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
		Dopamine hydrochloride : 3.2 mg/ml Docetaxel : 0.9 mg/ml		1754
		Dopamine hydrochloride : 3,2 mg/ml Doripenem : 5 mg/ml		2262
		Dopamine hydrochloride		3638
		Dopamine hydrochloride : 20 mg/ml Dobutamine hydrochloride : 10 mg/ml		3823
		Dopamine hydrochloride : 1.6 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041
		Dopamine hydrochloride : 3,2 mg/ml Doripenem : 5 mg/ml		2262
		Dopamine hydrochloride : 3.2 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Dopamine hydrochloride		3638
		Dopamine hydrochloride : 1.9 mg/ml Enalaprilate : 0.0125 mg/ml		1703
		Dopamine hydrochloride : 1,45 mg/ml Enalaprilate : 0,011 mg/ml		963
		Dopamine hydrochloride : 1.6 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Dopamine hydrochloride : 2 mg/ml		4832
		Dopamine hydrochloride : 3.2 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
		Dopamine hydrochloride : 0,8 mg/ml Eravacycline : 0,6 mg/ml		4434
		Dopamine hydrochloride : 1,6 mg/ml Esmolol hydrochloride : 10 mg/ml		384
		Dopamine hydrochloride : 8 mg/ml Esomeprazole sodium : 0.32 mg/ml		1506
		Dopamine hydrochloride : 8 mg/ml Esomeprazole sodium : 0.32 mg/ml		1506
		Dopamine hydrochloride : 3.2 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Dopamine hydrochloride : 1.6 mg/ml Famotidine : 2 mg/ml		215
		Dopamine hydrochloride : 1.6 mg/ml Famotidine : 0.2 mg/ml		398
		Dopamine hydrochloride : 3.2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Dopamine hydrochloride : 8 mg/ml Fentanyl citrate : 30 µg/ml		1506
		Dopamine hydrochloride : 8 mg/ml Fentanyl citrate : 30 µg/ml		1506
		Dopamine hydrochloride : 1,6 mg/ml Fentanyl citrate : 50 µg/ml		63
		Dopamine hydrochloride : 3.2 mg/ml Fentanyl citrate : 50 µg/ml		314
		Dopamine hydrochloride : 1,6 mg/ml Fluconazole : 2 mg/ml		255

		Dopamine hydrochloride : 3,2 mg/ml Flumazenil : 0,02 mg/ml		187
		Dopamine hydrochloride : 80 mg/ml Foscarnet sodium : 24 mg/ml		73
		Dopamine hydrochloride : 0.8 mg/ml Fosfomycin : 30 mg/ml		4055
		Dopamine hydrochloride : 0.8 mg/ml Fosfomycin : 30 mg/ml		4055
		Dopamine hydrochloride : 3,2 mg/ml Furosemide : 10 mg/ml		4389
		Dopamine hydrochloride : 3,2 mg/ml Furosemide : 10 mg/ml		3210
		Dopamine hydrochloride : 3.2 mg/ml Furosemide : 10 mg/ml		314
		Dopamine hydrochloride : 8 mg/ml Furosemide : 2 mg/ml		1506
		Dopamine hydrochloride		732
		Dopamine hydrochloride : 8 mg/ml Furosemide : 2 mg/ml		1506
		Dopamine hydrochloride : 0.8 mg/ml Gentamicin sulfate : 2 mg/ml		738
		Dopamine hydrochloride : 3.2 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Dopamine hydrochloride : 4 mg/ml		4835
		Dopamine hydrochloride : 3.2 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Dopamine hydrochloride Gentamicin sulfate		3638
		Dopamine hydrochloride : 1.6 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		403
		Dopamine hydrochloride : 1.6 mg/ml Heparin sodium : 50 UI/ml		317
		Dopamine hydrochloride : 40 mg/ml Heparin sodium : 1 UI/ml		1228
		Dopamine hydrochloride : 3,2 mg/ml Heparin sodium : 100 UI/ml		4389
		Dopamine hydrochloride : 1,6 mg/ml		4655
		Dopamine hydrochloride : 3.2 mg/ml Heparin sodium : 100 UI/ml		314
		Dopamine hydrochloride : 40 mg/ml Heparin sodium : 1 UI/ml		1228
		Dopamine hydrochloride : 1,7 >> 3,4 mg/ml Heparin sodium : 187 UI/ml		377
		Dopamine hydrochloride : 40 mg/ml Heparin sodium : 1 UI/ml		1228
		Dopamine hydrochloride : 0.8 mg/ml Heparin sodium : 200 UI/ml		738
		Dopamine hydrochloride : 3.2 mg/ml Hetastarch : 60 mg/ml		1721
		Dopamine hydrochloride : 40 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228

	Dopamine hydrochloride : 0.8 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		738
	Dopamine hydrochloride : 40 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
	Dopamine hydrochloride : 40 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
	Dopamine hydrochloride : 3.2 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
			3932
	Dopamine hydrochloride : 3,2 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Dopamine hydrochloride : 3,2 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Dopamine hydrochloride Imipenem-Cilastatin / Relebactam		4809
			467
	Dopamine hydrochloride : 8 mg/ml Insulin : 1 UI/ml		1506
			4389
			295
	Dopamine hydrochloride : 8 mg/ml Insulin : 1 UI/ml		1506
	Dopamine hydrochloride : 5 mg/ml Insulin aspart : 1 UI/ml		1508
	Dopamine hydrochloride : 5 mg/ml Insulin aspart : 1 UI/ml		1508
	Dopamine hydrochloride : 0.8 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Dopamine hydrochloride : 0.8 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Dopamine hydrochloride : 3.2 mg/ml		301
	Dopamine hydrochloride : 1.6 mg/ml Labetalol hydrochloride : 1 mg/ml		199
	Dopamine hydrochloride : 0.8 mg/ml Lidocaine hydrochloride : 2 mg/ml	RL	619
	Dopamine hydrochloride : 0.8 mg/ml Lidocaine hydrochloride : 2 mg/ml		619
	Dopamine hydrochloride : 0.8 mg/ml Mannitol : 20 mg/ml		732
	Dopamine hydrochloride : 0.8 mg/ml Meropenem : 1 & 20 mg/ml		266
	Dopamine hydrochloride : 8 mg/ml Methadone hydrochloride : 0.2 mg/ml		1506
	Dopamine hydrochloride : 0.8 mg/ml Methylprednisolone sodium succinate : 0.5 mg/ml		738
	Dopamine hydrochloride : 3.2 mg/ml Micafungin : 1.5 mg/ml		2108

		Dopamine hydrochloride : 8 mg/ml Midazolam hydrochloride : 4 mg/ml		1506
		Dopamine hydrochloride : 3,2 mg/ml	RL	4603
		Dopamine hydrochloride : 8 mg/ml Methadone hydrochloride : 0.2 mg/ml		1506
		Dopamine hydrochloride		3638
		Dopamine hydrochloride : 0.8 mg/ml Lidocaine hydrochloride : 4 mg/ml		738
		Dopamine hydrochloride : 3.2 mg/ml		1415
		Dopamine hydrochloride : 0.05 mg/ml		1338
		Dopamine hydrochloride : 1.6 mg/ml		939
		Dopamine hydrochloride : 3.2 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Dopamine hydrochloride : 2 mg/ml		4832
		Dopamine hydrochloride : 1.6 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Dopamine hydrochloride : 0.8 mg/ml Lidocaine hydrochloride : 2 mg/ml		619
		Dopamine hydrochloride : 32 mg/ml Meropenem : 50 mg/ml		4319
		Dopamine hydrochloride : 7,2 mg/ml		4924
		Dopamine hydrochloride : 40 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Dopamine hydrochloride : 3.2 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Dopamine hydrochloride : 1.6 mg/ml Levetiracetam : 10 mg/ml		4108
		Dopamine hydrochloride : 3.2 mg/ml Linezolid : 2 mg/ml		1925
		Dopamine hydrochloride : 3.2 mg/ml Lorazepam : 0.5 mg/ml		314
		Dopamine hydrochloride : 0.8 mg/ml Methylprednisolone sodium succinate : 5 mg/ml		132
		Dopamine hydrochloride : 0.8 mg/ml Metronidazole : 5 mg/ml		132
		Dopamine hydrochloride : 3.2 mg/ml		316
		Dopamine hydrochloride : 80 mg/ml Levofloxacin : 5 mg/ml		1072
		Dopamine hydrochloride : 1,6 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Dopamine hydrochloride : 3.2 mg/ml Midazolam hydrochloride : 1 mg/ml		295
		Dopamine hydrochloride : 8 mg/ml Midazolam hydrochloride : 4 mg/ml		1506
		Dopamine hydrochloride : 3.2 mg/ml Midazolam hydrochloride : 2 mg/ml		314
		Dopamine hydrochloride : 12.8 mg/ml Milrinone lactate : 0.8 mg/ml		813

	Dopamine hydrochloride : 3.2 mg/ml Milrinone lactate : 0.2 mg/ml		314
	Dopamine hydrochloride : 8 mg/ml Morphine hydrochloride : 1 mg/ml		1506
	Dopamine hydrochloride : 2 mg/ml Morphine hydrochloride : 0,2 mg/ml		4832
	Dopamine hydrochloride : 8 mg/ml Morphine hydrochloride : 1 mg/ml		1506
	Dopamine hydrochloride : 1.6 mg/ml Morphine sulfate : 1 mg/ml		62
	Dopamine hydrochloride : 3.2 mg/ml Morphine sulfate : 2 mg/ml		314
	Dopamine hydrochloride : 4 mg/ml Mycophenolate mofetil : 5,9 mg/ml		2192
	Dopamine hydrochloride : 3.2 mg/ml N-acetylcysteine : 200 mg/ml		3766
	Dopamine hydrochloride : 40 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Dopamine hydrochloride : 3.2 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
	Dopamine hydrochloride : 1.6 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
	Dopamine hydrochloride : 1.6 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
	Dopamine hydrochloride : 0.8 mg/ml Nitroglycerin : 0.4 mg/ml		1049
	Dopamine hydrochloride : 0.8 mg/ml Nitroglycerin : 0.4 mg/ml		1049
	Dopamine hydrochloride : 3.2 mg/ml Nitroglycerin : 0.4 mg/ml		314
	Dopamine hydrochloride : 5 mg/ml Nitroprusside sodium : 1.2 mg/ml		3381
	Dopamine hydrochloride : 5 mg/ml Norepinephrine bitartrate : 0.06 mg/ml		2879
	Dopamine hydrochloride : 8 mg/ml Norepinephrine bitartrate : 0.32 mg/ml		1506
	Dopamine hydrochloride : 5 mg/ml Norepinephrine bitartrate : 0,06 mg/ml		3177
	Dopamine hydrochloride : 8 mg/ml Norepinephrine bitartrate : 0.32 mg/ml		1506
	Dopamine hydrochloride : 3.2 mg/ml Norepinephrine bitartrate : 0.064 mg/ml		295
	Dopamine hydrochloride : 3.2 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
	Dopamine hydrochloride : 20 mg/ml Norepinephrine bitartrate : 0.96 mg/ml		3823
	Dopamine hydrochloride : 0.8 mg/ml Ondansetron hydrochloride : 0.32 mg/ml		132
	Dopamine hydrochloride : 0.8 mg/ml Ondansetron hydrochloride : 0.32 mg/ml		132
	Dopamine hydrochloride : 3.2 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152

		Dopamine hydrochloride Oxacillin sodium		3638
		Dopamine hydrochloride : 0.8 mg/ml Oxacillin sodium : 2 mg/ml		738
		Dopamine hydrochloride : 3,2 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Dopamine hydrochloride : 1.6 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Dopamine hydrochloride : 0.8 >> 3.2 mg/ml Pantoprazole sodium : 0.16 >> 0.8 mg/ml		1902
		Dopamine hydrochloride Pantoprazole sodium		2090
		Dopamine hydrochloride : 3.2 mg/ml Paracetamol : 10 mg/ml		4742
		Dopamine hydrochloride : 3.2 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Dopamine hydrochloride : 1.6 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Dopamine hydrochloride : 3.2 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Dopamine hydrochloride : 0.8 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Dopamine hydrochloride : 0.8 mg/ml Potassium chloride		738
		Dopamine hydrochloride : 40 mg/ml Potassium chloride : 40 mEq/l	RL	1228
		Dopamine hydrochloride : 40 mg/ml Potassium chloride : 40 mEq/l		1228
		Dopamine hydrochloride : 40 mg/ml Potassium chloride : 40 mEq/l		1228
		Dopamine hydrochloride : 2 mg/ml Propafenone hydrochloride : 1 mg/ml		925
		Dopamine hydrochloride : 1.6 mg/ml Propofol		660
		Dopamine hydrochloride : 3.2 mg/ml Propofol : 10 mg/ml	∅	300
		Dopamine hydrochloride : 25 mg/ml Propofol		4524
		Dopamine hydrochloride : 3.2 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Dopamine hydrochloride : 0.4 & 3.2 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
		Dopamine hydrochloride		3638
		Dopamine hydrochloride : 1,6 mg/ml Ranitidine hydrochloride : 0,5 mg/ml		396
		Dopamine hydrochloride : 0.4 & 3.2 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		210
		Dopamine hydrochloride : 0.4 & 3.2 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
		Dopamine hydrochloride : 0.4 & 3.2 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		210

	Dopamine hydrochloride : 3.2 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59	
	Dopamine hydrochloride : 40 mg/ml Salbutamol sulfate : 1 mg/ml		3216	
	Dopamine hydrochloride : 1.6 mg/ml Sargramostim : 6 §15 µg/ml		891	
	Dopamine hydrochloride : 7.2 mg/ml Sildenafil citrate : 0,6 mg/ml		4845	
	Dopamine hydrochloride : 1,6 mg/ml Sildenafil citrate : 0,4 mg/ml		3923	
	Dopamine hydrochloride Sodium bicarbonate		3638	
	Dopamine hydrochloride : 8 mg/ml Streptokinase : 30000 UI/ml		92	
	Dopamine hydrochloride : 8 mg/ml Sugammadex : 100 mg/ml		3372	
	Dopamine hydrochloride : 0,8 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801	
	Dopamine hydrochloride : 1,6 mg/ml Tacrolimus : 1000 µg/ml		479	
	Dopamine hydrochloride : 0.8 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827	
	Dopamine hydrochloride : 3.2 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254	
	Dopamine hydrochloride : 3.2 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254	
	Dopamine hydrochloride : 0.4 mg/ml Temocilline : 83.33 mg/ml		2231	
	Dopamine hydrochloride : 1.6 mg/ml Theophylline : 4 mg/ml		317	
		Dopamine hydrochloride : 40 mg/ml Thiopental sodium : 25 mg/ml		3767
		Dopamine hydrochloride : 3.2 mg/ml Thiopental sodium : 25 mg/ml		314
	Dopamine hydrochloride : 3.2 mg/ml Thiotepa : 1 mg/ml		249	
	Dopamine hydrochloride Tigecycline		3332	
	Dopamine hydrochloride Tirofiban		1512	
	Dopamine hydrochloride : 0.2 & 3.2 mg/ml Tirofiban : 50 µg/ml		1420	
	Dopamine hydrochloride : 0.2 & 3.2 mg/ml Tirofiban : 50 µg/ml		1420	
	Dopamine hydrochloride : 0,6 mg/ml Treprostinil : 0,5 mg/ml		4407	
		Dopamine hydrochloride : 40 mg/ml Treprostinil : 0,5 mg/ml		4407
		Dopamine hydrochloride : 6 mg/ml Treprostinil : 0,5 mg/ml		4407
		Dopamine hydrochloride : 3,2 mg/ml Treprostinil : 0,5 mg/ml		4407

	Dopamine hydrochloride : 0,6 >> 40 mg/ml Treprostiniil : 0,004 >>0,076 mg/ml		4407
	Dopamine hydrochloride : 1,6 mg/ml Valproic acid : 10 mg/ml		3942
	Dopamine hydrochloride : 0.4 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
	Dopamine hydrochloride : 4.2 mg/ml Vasopressin : 2 & 4 UI/ml		1801
	Dopamine hydrochloride : 3.2 mg/ml Vasopressin : 0.2 UI/ml		2017
	Dopamine hydrochloride : 1.6 mg/ml Vecuronium bromide : 0.1 mg/ml		402
	Dopamine hydrochloride : 3.2 mg/ml Vecuronium bromide : 1 mg/ml		314
	Dopamine hydrochloride : 0.4 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
	Dopamine hydrochloride : 0.4 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
	Dopamine hydrochloride : 1,6 mg/ml Warfarin sodium : 2 mg/ml		315
	Dopamine hydrochloride : 1.6 mg/ml Zidovudine : 4 mg/ml		337
	Dopamine hydrochloride : 4 mg/ml	PI ¹⁴⁸	4835



način davanja lijeka



Bibliografija

	Vrsta	Publikacija
3	Časopis	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
36	Časopis	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59	Časopis	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Časopis	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.

63	Časopis	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Časopis	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Časopis	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
92	Časopis	Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 606-608.
93	Časopis	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Časopis	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
132	Časopis	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
176	Časopis	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Časopis	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
187	Časopis	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
192	Časopis	Peddicord TE, Olsen KM, ZumBrunnen TL, Warner DJ, Webb L. Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 1417-1419.
196	Časopis	Pramar Y, Das Gupta V, Neal Gardner S, Yau B. Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes. J Clin Pharm Ther 1991 ; 16: 203-207.
197	Časopis	Allwood MC. The stability of four catecholamines in 5% glucose infusions. J Clin Pharm Ther 1991 ; 16: 337-340.
198	Časopis	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
199	Časopis	Hassan E, Leslie J, Martir-Herrero ML. Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 2143-2145.
206	Časopis	Sautou-Miranda V, Gremeau I, Chamard I, Cassagnes J, Chopineau J. Stability of dopamine hydrochloride and of dobutamine hydrochloride in plastic syringes and administration sets. Am J Health-Syst Pharm 1996 ; 53: 186.
210	Časopis	Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807.

214	Časopis	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
215	Časopis	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
240	Časopis	Lam XM, Ward CA, de C du M?e CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
249	Časopis	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Časopis	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
255	Časopis	Ishisaka DY. Visual compatibility of fluconazole with drugs given by continuous infusion. Am J Hosp Pharm 1994 ; 51: 2290,2292.
266	Časopis	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
280	Časopis	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
288	Časopis	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
295	Časopis	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Časopis	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Časopis	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Časopis	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
314	Časopis	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
315	Časopis	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316	Časopis	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.

317	Časopis	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
336	Časopis	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Časopis	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
377	Časopis	Pereira-Rosario R, Utamura T, Perrin JH. Interaction of heparin sodium and dopamine hydrochloride in admixtures studied by microcalorimetry. Am J Hosp Pharm 1988 ; 45: 1350-1352.
384	Časopis	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	Časopis	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
396	Časopis	Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058.
398	Časopis	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Časopis	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
403	Časopis	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.
467	Časopis	Ishisaka DY, van Vleet J, Marquardt E. Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm 1991 ; 48: 2442-2443.
479	Časopis	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
524	Časopis	Farquhar Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 1911.
619	Časopis	Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. Am J Hosp Pharm 1982 ; 39: 1013-1015.
660	Časopis	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
705	Časopis	Lee YC, Malick W, Amann AH, Baaske DM, Shah JJ, Wagenknecht DM, Carter JE. Bretylum tosylate admixture compatibility. II : Dopamine, lidocaine, procainamide, and nitroglycerin. Am J Hosp Pharm 1981 ; 38: 183-187.

732	Časopis	Gardella LA, Zaroslinski JF, Possley LH. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 1: Stability with common intravenous fluids. Am J Hosp Pharm 1975 ; 32: 575-578.
738	Časopis	Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584.
813	Časopis	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
891	Časopis	Matsuura G. Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents. Hosp Pharm 1992 ; 27: 200, 202, 209.
921	Časopis	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
925	Časopis	Dupuis LL, Trope A, Giesbrecht E, Wong B. Compatibility and stability of propafenone hydrochloride with five critical-care medications. Can J Hosp Pharm 1998 ; 51: 55-57.
939	Časopis	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
963	Časopis	Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. J Clin Pharm Ther 1990 ; 15: 371-376.
1036	Časopis	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	Časopis	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1049	Časopis	Klamerus KJ, Ueda CT, Newton DW. Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm 1984 ; 41: 303-305.
1057	Časopis	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1058	Časopis	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1072	Časopis	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1221	Časopis	Dahlin PA, Paredes SM. Visual compatibility of dobutamine with seven parenteral drug products. Am J Hosp Pharm 1980 ; 37: 460,464.
1228	Časopis	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.

1249	Časopis	Dandurand KR, Stennett DJ. Stability of dopamine hydrochloride exposed to blue-light phototherapy. Am J Hosp Pharm 1985 ; 42: 595-597.
1315	Časopis	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1338	Časopis	Baptista RJ, Dumas GJ, Bistran BR, Condella F, Blackburn GL. Compatibility of total nutrient admixtures and secondary cardiovascular medications. Am J Hosp Pharm 1985 ; 42: 777-778.
1397	Časopis	Garner ST, Murdoch JM. Dopamine dilutions. Pharm J 1990 ; 244: 218.
1410	Časopis	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Časopis	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1420	Časopis	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1423	Časopis	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Časopis	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Časopis	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1506	Časopis	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Časopis	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratorija	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1625	Časopis	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Časopis	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1698	Časopis	Körner A, Bonnacker I. Stabilität von dopaminhydrochlorid (Dopamine Solvay®) in mischungen mit infusionslösungen. Krankenhauspharmazie 1997 ; 18: 474-478.
1703	Časopis	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.

1712	Časopis	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Časopis	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Časopis	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Časopis	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1801	Časopis	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	Časopis	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1820	Časopis	Braenden JU, Stendal TL, Fagernaes CB. Stability of dopamine hydrochloride 0.5 mg/ml in polypropylene syringes. J Clin Pharm Ther 2003 ; 28: 471-474.
1902	Časopis	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925	Časopis	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	Časopis	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1944	Časopis	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1953	Časopis	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1964	Časopis	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1965	Časopis	Brustugun J, Kristensen S, Tonnesen HH. Photostability of sympatomimetic agents in commonly used infusion media in the absence and presence of bisulfite. PDA J Pharm Sci Technol 2004 ; 58, 6: 296-308.
1982	Časopis	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Časopis	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2018	Časopis	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.

2090	Časopis	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Časopis	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Časopis	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	Časopis	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2192	Časopis	Cochran BG, Sowinski KM, Fausel C, Overholser BR. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2231	Časopis	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	Časopis	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Časopis	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Časopis	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Časopis	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2271	Laboratorija	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
2879	Plakat	Imesch G., Humbert-Delaloye V., Berger M., Pannatier A. Compatibilité entre amiodarone, catecholamines et/ou nitroprussiate de sodium, administré en continu par voie veineuse aux soins intensifs adultes. GSASA Congress - Lucerne - Switzerland 2008
3012	Časopis	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Časopis	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3177	Plakat	Humbert-Delaloye V, Berger M, Pannatier A. Compatibilités physico-chimique entre catécholamines, amiodarone, et/ou nitroprussiate de sodium intraveineux. 16èmes JFSPH, Sion, 18-19 novembre 2010 2010

3201	Časopis	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233-236.
3210	Časopis	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3216	Časopis	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Časopis	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Časopis	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratorija	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3372	Časopis	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3381	Časopis	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Gattlen L, Pannatier A. In vitro compatibility of various cardioactive drugs during simulated Y-site administration. EJHP 2013 ; 20:110-116.
3385	Časopis	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Časopis	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3595	Laboratorija	Aciclovir - Summary of Product Characteristics Hospira 2009
3638	Laboratorija	Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics Hospira 2010
3712	Časopis	Ghanayem N.S, Lee L, Nelson T, Wong S, Gordon G.B, Markdante K et al. Stability of dopamine and epinephrine solutions up to 84 hours. Pediatr Crit Care Med 2001 ; 2, 4: 315-317.
3715	Časopis	Mauro V.F, Howard M.S, Boddu S.H.S, Churchwell M.D. Compatibility of conivaptan injection with select cardiovascular medications. Am J Health-Syst Pharm 2014 ; 71:1534-1535
3759	Časopis	Igarashi K, Kawahara M. Examination of the cause of changing solution color by mixing aminophylline and dopamine, the compatibility of which was indicated by the supplier. Yakugaku Zasshi 2014 ; 134, 2: 293-298.
3766	Časopis	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Časopis	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.

3823	Časopis	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Časopis	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Plakat	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3923	Časopis	Luu Y, Thigpen J, Brown S.D. Stability of sildenafil in combination with heparin and dopamine. Am J Health-Syst Pharm 2017 ; 74, 1: e64-e71
3932	Laboratorija	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3942	Časopis	Frank M.I, Boddu S.H.S, Mauro V.F., Churchwell M.D. Physical compatibility of valproate sodium injection with dobutamine and dopamine. Am J Health-Syst Pharm 2017 ; 74, 5: 280-281.
3964	Časopis	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Časopis	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4108	Časopis	Cruz K, Churchwell M, Mauro V, Boddu. Physical compatibility of levetiracetam injection with heparin, dobutamine, and dopamine. Am J Health-Syst Pharm 2018 ;75;8:510-512
4145	Časopis	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Časopis	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Časopis	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédomidine, le lévamisentan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4407	Časopis	Bustin A, Ramsey Z, Hanna B, Kaushal G. Compatibility of treprostinil sodium and dopamine hydrochloride during simulated Y-site administration. Am J Health-Syst Pharm 2020 ;77,8:649-657.
4433	Časopis	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.

4434	Časopis	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4491	Časopis	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4524	Plakat	Stucki C, Sautter A-M, Bonnabry P. Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. ESCP Symposium, Geneva, Switzerland 2009
4603	Časopis	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratorija	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4651	Časopis	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4655	Časopis	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4742	Časopis	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Časopis	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4809	Laboratorija	Recarbrio® - Résumé des caractéristiques du produit 2024
4818	Laboratorija	Giapreza 2.5mg per ml concentrate for solution for infusion - Summary of Product Characteristics Updated 30-Jun-2022 PAION UK Ltd 2022
4832	Časopis	Nilsson N, Storesund I, Tho I, Nezvalova Henriksen K. Co administration of drugs with parenteral nutrition in the neonatal intensive care unit—physical compatibility between three components. Eur J Pedia 2022 ; 181:2685–2693.
4835	Časopis	Hammond S, Wignell A, Cooling P, Barrett D.A, Davies P. Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs. Intensive Care Medecine Experimental 2020 8:25.
4837	Časopis	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.
4845	Časopis	De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. Pharmaceutics 2024 ;1 6, 419.

4924	Časopis	Senarathna G, Strunk T, Petrovski M, Woodland S, Martinez J, Chuang V, Batty K. Physical compatibility of lipid emulsions and intravenous medications used in neonatal intensive care settings EJHP 2023 2025;32:
4981	Laboratorija	KETESSE 50 mg/2 ml, solution injectable/pour perfusion - Résumé des caractéristiques du produit. MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. 2024
5042	Laboratorija	Dexdor 100 micrograms/ml concentrate for solution for infusion - Summary of Product Characteristics. Orion Corporation 2016

 kardiotonici	 injekcija
 Nekomercijalni	 Stabilizacija rješenja
 Kontejner	 Molekula
 koncentracija	 temperatura
 Konzerviranje	 Trajanje stabilnosti
 biosimilar	 proturječni podaci
 Bibliografija	 čaša
 natrijumkorid 0,9%	 svjetlost
 sat	 glukoza 5%
 Zaštićeno od svjetlosti	 dan
RL Ringer laktat	 polivinilklorid
 špric polipropilen	 nespecifičan
 Sa i bez svjetlosti	 glukoza 10%
 nespecifičan	 Stabilnost mješavine
 sredstvo za rastapanje	 molekula
 NaCl 0,45% glukoza 2,5%	 natrijumklorid 0,45%
 polietilen	 polipropilen
 Stabilizacijski faktor	 izaziva
 Degradacija	 Pojačana stabilnost
 Parenteralna prehrana (lipidima)	 NaHCO ₃
 Kompatibilnosti	 Promjena boje je nakon 2 sata
 inkompatibilan	 Neodređena nespojivost
 Kompatibilan	 Kemijska nestabilnost
 čista voda za injektiranje	 Padavine nakon 4 sata
 Neposredne oborine	 Promjena boje
 nijedan	 NaCL 0,9% + bakteriostatična
 Zamućenost u jednom satu	 Parenteralna prehrana (bezlipidna)
 Promjena boje je nakon 4 sata	 Neposredna zamućenost
 Plasmalyte 148 (Baxter)	 Normosol®
 Specifična otapala	 Padavine nakon 1 sata

 Nestabilnost emulzije nakon 6 sati	 Plasmalyte 148 dextrose 5% (Baxter)
 način davanja lijeka	 intravenozna infuzija
 trajna perfuzija	 Bibliografija
 rječnik	